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Abstract: Mortality rates attributable to coronary heart disease have declined in recent years,
possibly related to changes in clinical presentation patterns and use of proven secondary prevention strategies. Chronic stable angina (CSA) remains prevalent, and the goal of treatment is control
of symptoms and reduction in cardiovascular events. Ranolazine is a selective inhibitor of the
late sodium current in myocytes with anti-ischemic and metabolic properties. It was approved
by the US Food and Drug Administration in 2006 for use in patients with CSA. Multiple, randomized, placebo-controlled trials have shown that ranolazine improves functional capacity and
decreases anginal episodes in CSA patients, despite a lack of a significant hemodynamic effect.
Ranolazine did not improve cardiovascular mortality or affect incidence of myocardial infarction
in the MERLIN (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation
Acute Coronary Syndrome)-TIMI (Thrombolysis In Myocardial Infarction) 36 trial, but significantly decreased the incidence of recurrent angina. More recently, ranolazine has been shown
to have beneficial and potent antiarrhythmic effects, both on supraventricular and ventricular
tachyarrhythmias, largely due to its inhibition of the late sodium current. Randomized controlled
trials testing these effects are underway. Lastly, ranolazine appears to be cost-effective due to its
ability to decrease angina-related hospitalizations and improve quality of life.
Keywords: ranolazine, chronic stable angina, coronary artery disease
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Mortality rates attributable to cardiovascular disease have declined in recent decades,
but the burden of disease remains high. From 1999 to 2009, the relative rate of death
attributable to cardiovascular disease declined by 32.7%. However, in 2009, cardiovascular disease still accounted for 32.3% of all deaths, or one in every three deaths
in the USA.1
According to the most recent data published by the American Heart Association,
coronary heart disease (CHD) alone caused approximately one of every six deaths in the
USA in 2009. On the basis of data from the National Health and Nutrition Examination
Survey 2007–2010, an estimated 15.4 million Americans have CHD, with a prevalence
of 6.4% in the US population. From 1999 to 2009, the annual death rate attributable
to CHD declined by 40.3% and the actual number of deaths declined by 27.1%.2 The
decline in CHD deaths partly reflects a shift in the pattern of clinical presentation of
acute myocardial infarction. In the past decade, there has been a marked decline in
ST-segment elevation myocardial infarction.3 Further, after 1980 and 2000 data were
compared, it was estimated that approximately 47% of the decrease in CHD deaths was
attributable to treatments, including secondary preventive therapies, initial treatment
after acute myocardial infarction, and revascularization for chronic angina.4
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Angina pectoris, ie, chest pain or discomfort that results
from insufficient blood flow to the heart muscle, was accurately reported by William Heberden in 1772.5 Chronic stable
angina (CSA) is usually described as predictable chest pain
on exertion or when under mental or emotional stress. Only
18% of acute coronary syndromes are preceded by longstanding CSA. Estimates from the National Health and Nutrition
Examination Survey 2007–2010 show a prevalence of CSA
of 7.8 million people (3.2% of the US population). The
annual rates per 1,000 population of new episodes of CSA for
nonblack men are 28.3 for those aged 65–74 years, 36.3 for
those aged 75–84 years, and 33.0 for those aged $85 years.
For nonblack women in the same age groups, the rates are
14.1, 20.0, and 22.9, respectively. For black men, the rates
are 22.4, 33.8, and 39.5, and for black women, the rates are
15.3, 23.6, and 35.9, respectively.6
The two aims of pharmacological management for
CSA are to obtain relief of symptoms and to prevent
cardiovascular events. These are usually achieved by pharmacological or lifestyle interventions that reduce plaque
progression, stabilize plaque by reducing inflammation,
and prevent thrombosis, should plaque rupture or erosion
occur.
First-line treatment is indicated with beta-blockers and/or
calcium channel blockers to control heart rate and symptoms,
as well as nitrates for symptomatic relief. Prevention of
cardiovascular events is usually accomplished by use of antiplatelet agents, statins, and possibly angiotensin-converting
enzyme inhibitors or angiotensin II receptor antagonists.
Coronary revascularization generally improves survival
among certain subgroups of patients, particularly those with
severe left main coronary stenosis.7 Ranolazine is a novel
agent with anti-ischemic and metabolic properties, and was
approved by the US Food and Drug Administration in 2006
for the treatment of patients with CSA.8

Overview of pharmacology
of ranolazine
Ranolazine is a selective inhibitor of the late sodium current
(INaL) in cardiomyocytes and has anti-ischemic and metabolic properties. Its extended-release (ER) form was approved
in doses of 500 mg twice daily and 1,000 mg twice daily,
based on clinical symptoms. After oral administration, peak
plasma concentrations of ranolazine are reached between
2 and 5 hours. Ranolazine is extensively metabolized in
the gut and liver, and its absorption is highly variable.
The elimination half-life of ranolazine is 1.4–1.9 hours,
but is apparently prolonged, on average, to 7 hours for
the ER formulation as a result of extended absorption
354
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( flip-flop kinetics). Steady state is generally achieved within
3 days of twice-daily dosing.9,10
The drug is metabolized mainly by cytochrome P450
(CYP) 3A4 and, to a lesser extent, by CYP2D6. This occurs
rapidly and extensively in the liver and intestine; less than
5% is excreted unchanged in urine and feces.9 Ranolazine is
a weak inhibitor of CYP3A4 and CYP2D6. The interactions
of ranolazine with inhibitors and substrates of the CYP3
family have been studied.11 Ketoconazole was associated
with the largest effect, increasing the area under the plasma
concentration time curve of ranolazine by 3.9-fold, followed
by diltiazem (1.5-fold), whereas simvastatin was too weak
an inhibitor to significantly affect the pharmacokinetic
parameters of ranolazine. Further, ranolazine is a substrate
for and transported by P-glycoprotein. Verapamil is a potent
P-glycoprotein inhibitor and also inhibits CYP3A4, and
can lead to a 2–3-fold increase in the area under plasma
concentration time curve for ranolazine.9 Concomitant use
of ranolazine and drugs transported by P-glycoprotein (such
as digoxin) results in increased exposure to the latter and the
dose may have to be adjusted.
Ranolazine is contraindicated in patients receiving strong
CYP3A4 inhibitors or inducers and those with liver cirrhosis.
It is also recommended to limit the dose to 500 mg daily in
those receiving moderate CYP3A4 inhibitors, (diltiazem,
verapamil, erythromycin), and to limit the dose of simvastatin
to 20 mg when used in combination with ranolazine.10
Inhibition of the rapidly activating delayed rectifier
potassium current (IKr) by ranolazine explains the effect
of the drug to prolong ventricular and atrial action potential
duration, as well as the small QTc interval prolongation
observed in clinical trials. Despite this effect, ranolazine
does not induce torsades de pointes and possibly suppresses
long QT-related ventricular arrhythmias, as shown in long
QT experimental trials.12,13
The antianginal mechanism of action of ranolazine has
not been fully elucidated. Initial studies proposed myocardial metabolic modulation as the predominant mechanism
of action, with minimal or no effect on heart rate, coronary
blood flow, and systemic arterial blood pressure.14 In the
healthy heart, fatty acids are the primary fuel source for
the generation of adenosine triphosphate (ATP).15 During
ischemia, fatty acid and pyruvate oxidation both decrease
as glycolysis becomes the predominant route for ATP
production. Glycolytic regeneration of ATP leads to intracellular acidosis, intracellular calcium overload, and contractile
dysfunction.16 Results of early studies suggested that ranolazine improved myocardial energy metabolism by reducing
fatty acid oxidation and increasing glucose oxidation.17
Vascular Health and Risk Management 2014:10
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However, these effects require relatively high concentrations of ranolazine, whereas improvement in cardiac function and clinical status occur in the presence of much lower
concentrations.18
In recent years, the research focus has shifted toward
INaL as a contributor to the pathogenesis of angina.19,20
Activation of cardiac myocytes in normal hearts leads
to rapid cell depolarization (the upstroke of the action
potential) through brief opening of membrane sodium
channels (INa). Most sodium channels are inactivated
within a few milliseconds, but a few may continue to
open and close spontaneously during the action potential
plateau for reasons that are not understood. This current
has been referred to as INaL. Under normal conditions,
INaL constitutes only 1% of peak INa. Voltage-dependent
calcium channels then open and initiate a large outflow
of sarcoplasmic calcium into the cytoplasm, initiating
myocardial contraction through the coupling of actin and
myosin filaments.19–21
Several pathological conditions, including ischemia and
heart failure, can significantly increase the late component
of the sodium channel current.22,23 This may be followed by
increases in myocyte membrane sodium calcium exchange,
resulting intracellular increases of calcium, and excessive
calcium loading of the sarcoplasmic reticulum. Calcium
overload of myocardial cells is associated with electrical
instability, increased diastolic and reduced systolic force
generation, and an increase in oxygen consumption.24 The
increase in diastolic tension may cause compression of
the vascular space and further reduction of blood flow and
oxygen delivery (Figure 1).25–27
Ranolazine has been shown to selectively inhibit INaL in
canine and pig models without affecting the fast sodium current responsible for the upstroke of the action potential.12–28
The effect of ranolazine on INaL is more pronounced
in ischemic or failing myocytes in which the current is
amplified. Therefore, ranolazine has the potential to disrupt
the consequences of myocardial ischemia by reducing excess
sodium influx, reducing calcium overload, and the noxious
increase in left ventricular wall tension.
Further, ranolazine significantly inhibits the rapidly activating component of the delayed rectifier or IKr. Although
inhibition of IKr by ranolazine prolongs the action potential
duration, inhibition of INaL and the late ICa2+ (which is
also affected) shorten the duration of the action potential
such that the net effect on its duration, or QTc, is usually
modest (Figure 2).12 Experimental and clinical studies have
shown that ranolazine has antiarrhythmic effects in both the
ventricles and atria.13
Vascular Health and Risk Management 2014:10
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Disease(s) and pathological states linked to imbalance of O2
supply/demand

I NaL

Na+-entry ([Na+]i)
NCX

Cytosolic Ca2+

Electrical instability
• Afterpotentials
• Beat-to-beat APD

Mechanical dysfunction
• Abnormal contraction
and relaxation

• Arrhythmias (VT)

• Diastolic tension

Figure 1 Increase in intracellular sodium concentration ([Na+]i) in pathological
conditions linked to imbalances between oxygen supply and demand causes calcium
entry through the Na+/Ca2+ exchanger (NCX).
Notes: An enhanced late sodium current (INaL) contributes to [Na+]
i-dependent calcium overload, leading to electrical instability and mechanical
dysfunction. Copyright © 2006, BMJ Publishing Group Ltd. Reproduced from
Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a
potential cardioprotective principle: effects of the late sodium current inhibitor
ranolazine. Heart. 2006;92(Suppl 4):iv6–iv14, with permission from BMJ Publishing
Group Ltd.20
Abbreviations: APD, action potential duration; VT, ventricular tachycardia.

Use of ranolazine in chronic
stable angina
The efficacy of ranolazine in CSA patients has been
demonstrated in several randomized trials. Early trials
used the immediate-release formulation administered three
times daily and failed to show superior antianginal and antiischemic effects over placebo.29,30 Subsequently, the ER version was tested in several clinical studies, the major results
of which are summarized in Table 1.
MARISA (Monotherapy Assessment of Ranolazine In Stable Angina) was a randomized, multicenter,
double-blind, dose-finding study utilizing ranolazine ER
as monotherapy for angina.31 A total of 191 patients with
documented coronary artery disease and exercise-limiting
angina were enrolled. Existing antianginal treatment (with
the exception of sublingual nitroglycerin) was discontinued
prior to randomization. Ranolazine ER at doses of 500
mg, 1,000 mg, and 1,500 mg or placebo, was administered
twice daily for one week in this four-period crossover study.
Exercise treadmill tests were performed at the end of each
study period to coincide with peak (4 hours) and trough
(12 hours) plasma levels. Compared with placebo, ranolazine
demonstrated significant dose-dependent improvements in
submit your manuscript | www.dovepress.com
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Twitch
Figure 2 Relation between peak and late sodium current and ventricular action potential (AP) and contraction.
Notes: INaL is the current associated with the slow inactivating component of the INa (sodium channel). Panels A and B illustrate a normal and an increased INa (due
to impaired inactivation of the Na+ channel), respectively. The enhanced late INa is accompanied by delayed ventricular repolarization (long APs and occasional early
afterdepolarizations) and abnormal twitch (contraction composed of a phasic and a tonic component). Copyright © 2004, Oxford University Press. Reproduced from
Belardinelli L, Antzelevitch C, Fraser H, Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium dependent calcium
overload and its detrimental effects on cardiomyocyte function, European Heart Journal, 2004;6(Suppl I):I3–I7, by permission of Oxford University Press.23

total exercise duration, time to angina, and time to 1 mm
ST-segment depression at both peak and trough levels, with
minimal effects on heart rate and blood pressure. Safety of
the drug was also studied in this trial, with some patients
continuing in an open-label, observational follow-on study.
One-year survival in this group was in line with the predicted rate.
Overall, the drug was well tolerated, with less than 8% of
patients discontinuing ranolazine because of adverse effects.
The majority of these patients were on the 1,500 mg dose,
which was related to higher rates of dizziness, nausea, asthenia, and constipation. Dose-related increases in the corrected
QT interval were also noted, although this was not a reason
for drug discontinuation. Thus, the MARISA study demonstrated that ranolazine was effective and safe as monotherapy
for angina. The optimum risk to benefit ratio was noted
in the lower doses, with the authors suggesting starting at
500 mg and titrating upwards to 750 mg or 1,000 mg twice
daily as needed to achieve angina control. In contemporary
clinical practice, ranolazine is not used as the sole antianginal
agent, making the above findings less applicable to current
patients.
In contrast with MARISA, the CARISA (Combination
Assessment of Ranolazine In Stable Angina) trial was
intended to evaluate the efficacy of ranolazine ER when used
in conjunction with standard doses of typical antianginal

356

submit your manuscript | www.dovepress.com

Dovepress

drugs (atenolol 50 mg/day, diltiazem 180 mg/day, or
a mlodipine 5 mg/day), prescribed based on physician
discretion.32 This was a much larger multicenter international trial, randomizing 823 patients with severe chronic
angina to receive ranolazine ER 750 mg or 1,000 mg twice
daily, or placebo (with background antianginal therapy for
all patients) for 12 weeks in a three-group, parallel, doubleblind design. Treadmill exercise testing at peak and trough
plasma levels was performed after 2, 6 (trough only), and
12 weeks of treatment. Increase in trough symptom-limited
exercise duration (the primary endpoint) was significantly
greater in both ranolazine groups compared with placebo.
The time to onset of angina at trough and peak plasma
concentrations was also greater with ranolazine. The time
to $1 cm ST-segment depression at peak concentration
was longer than with placebo in both ranolazine arms,
although the same parameter at trough concentrations did
not significantly differ between the two doses of ranolazine
tested. Frequency of angina attacks and nitroglycerin use
were significantly reduced in both ranolazine groups, and
like in the MARISA trial, these benefits were noted in the
absence of any significant hemodynamic effects. Importantly, treatment with other antianginals did not blunt the
response to ranolazine.
Several subgroup analyses of this trial were reported.
Among 258 patients considered to be treated with

Vascular Health and Risk Management 2014:10
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Randomized, doubleblind, four-period,
crossover
Randomized, threegroup, parallel, doubleblind, placebo-controlled

Randomized, parallel,
double-blind, placebocontrolled

Randomized, parallel,
double-blind, placebocontrolled

MARISA31

ERICA37

TERISA40

3,279

462

281

554 (279 to lower
dose, 275 to
higher dose)

191

Active

Participants

3,281

465

284

269

Control

Ischemic symptoms at rest,
presenting within 48 hours, at
least one moderate to high risk
feature

CAD, CSA $3 months and
$3 episodes of angina per week
during a $2-week qualification
period despite treatment with
amlodipine 10 mg/day
CAD, type 2 diabetes, CSA
$3 months on one or two AA

CAD, CSA $3 months,
$1 mm ST-segment depression
between 3 and 9 min on ETT
CAD, CSA $3 months, $1 mm
ST-segment depression between
3 and 9 min on ETT

Inclusion criteria

Initial IV loading
followed by 1,000 mg
twice daily/median
348 days

500 and 1,000 mg
twice daily/3 weeks

1,000 mg twice
daily/6 weeks

500, 1,000, and
1,500 mg twice daily/
4 weeks
750 and 1,000 mg
twice daily/12 weeks

Dose/duration

One to two other AA
(beta-blockers, calcium
channel blockers, longacting nitrates)
Conventional ACS
therapy

Nonbackground AA
stopped $5 days before
ETT. Atenolol 50 mg,
amlodipine 5 mg, or
diltiazem 180 mg once
daily, NTG PRN
Amlodipine continued,
no other AA except
NTG PRN and longacting nitrates

All AA discontinued
except NTG PRN

Other medications

Weekly average
angina frequency
from weeks 2–8
of treatment
Composite of
cardiovascular death,
MI, or recurrent
ischemia

Weekly average
angina frequency

Total exercise
duration at trough
(12 hours post dose)
Total exercise
duration at trough
(12 hours post dose)

Primary endpoint

No change

Decreased

Decreased

Increased
at both
doses

Increased
at all doses

Result

Abbreviations: CAD, coronary artery disease; CSA, chronic stable angina; ETT, exercise treadmill test; AA, antianginals; NTG, nitroglycerin; IV, intravenous; PRN, as needed; ACS, acute coronary syndrome; MI, myocardial infarction; MARISA,
Monotherapy Assessment of Ranolazine In Stable Angina; CARISA, Combination Assessment of Ranolazine In Stable Angina; ERICA, Efficacy of Ranolazine In Chronic Angina;TERISA,Type 2 Diabetes Evaluation of Ranolazine in Subjects With
Chronic Stable Angina; MERLIN, Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome; TIMI, Thrombolysis In Myocardial Infarction.

MERLIN-TIMI 3641 Randomized, parallel,
double-blind, placebocontrolled

CARISA32

Trial design

Trial

Table 1 Major randomized clinical trials of ranolazine extended-release
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maximally tolerated doses of beta-blockers or calcium channel blockers (based on the parameters of
systolic blood p ressure #100 mmHg, a resting heart
rate #60 beats per minute, and/or an electrocardiographic
PR interval $200 msec) ranolazine improved exercise
tolerance at both trough and peak concentrations, along
with significant lengthening in the times to angina onset
and $1 mm ST-segment depression at peak but not trough
concentrations. Consistent significant reductions were also
noted in frequency of angina and nitroglycerin consumption.33
Similarly, when patients with diabetes (n=189) were studied
separately, there was no significant interaction with respect to
the benefits of ranolazine on symptom-limited or ischemialimited exercise duration, angina frequency, or nitroglycerin
use.34 Additionally, in 237 patients with New York Heart
Association class I or II heart failure, the effects of ranolazine
ER on improving exercise tolerance prevailed.35
Overall, treatment was well tolerated at both doses.
Adverse events were reported in 31.2% and 32.7% of
ranolazine ER 750 mg and 1,000 mg recipients, respectively,
compared with 26.4% of placebo-treated patients. Constipation, dizziness, nausea, and asthenia were most commonly
reported. Five patients in the ranolazine ER 1,000 mg arm
experienced syncope without evident ventricular tachyarrhythmia, although significant dose-related increases in the
corrected QT interval were seen with both doses of ranolazine.
Among the 750 ranolazine-treated patients who continued on
to an open-label, observational follow-on study, survival rates
of 98.4% and 95.9% after 1 or 2 years of follow-up, respectively, were reported, and were similar to expected rates. Thus,
there was no long-term signal of significant harm.
The ROLE (Ranolazine Open Label Experience) program
included 746 patients who completed the MARISA and CARISA trials and consented to participate in an open-label, 6-year
follow-on extension.36 After 2.8 years of follow-up, 9.7% discontinued ranolazine due to adverse events, with age $64 years
being the only predictor of drug discontinuation. Mean QTc
interval was prolonged by a statistically significant 2.4 msec,
although this did not lead to any discontinuations or reported
torsades de pointes. Annual mortality was reported at 2.8%
compared with .5% as predicted by the Duke Treadmill Score.
Thus, long-term therapy with ranolazine appeared to be well
tolerated, with no indication of a higher than predicted mortality in this population with stable ischemic heart disease.
The objective of the ERICA (Efficacy of Ranolazine In
Chronic Angina) trial was to specifically examine the antianginal efficacy of ranolazine when used with maximum recommended doses of amlodipine.37 In this study, 565 patients
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with three or more episodes of chronic stable angina per week,
despite receiving amlodipine 10 mg/day, were randomized to
additional treatment with ranolazine ER 1,000 mg or placebo
twice daily for 6 weeks. Patients were allowed to be on longacting nitrates, but not on beta-blockers. Compared with
placebo, ranolazine significantly reduced the weekly average
frequency of self-reported angina episodes (primary endpoint)
and nitroglycerin use. The therapeutic effect appeared to be
more prominent in those with more severe baseline angina.
In particular, significant reductions in nitroglycerin use and
Seattle Angina Questionnaire angina frequency were observed
for patients with more than 4.5 anginal episodes per week,
but only in angina frequency for those with less frequent
baseline symptoms.
Overall, ranolazine remained well tolerated and did not
cause any notable change in hemodynamic parameters.
Compared with 35.3% of placebo recipients, 39.9% of
ranolazine ER recipients reported adverse events, mostly of
mild to moderate severity. Again, constipation was commonly
reported, in addition to peripheral edema, dizziness, nausea,
and headache. Therefore, the ERICA trial confirmed the
incremental antianginal effect of ranolazine in addition to
maximal-dose amlodipine.
Data from CARISA and ERICA were pooled to compare
endpoints between patients aged $70 years (n=363) and
those ,70 years of age (n=1,024). The efficacy of ranolazine
remained similar in both age groups, although nonserious
adverse effects were more common in the elderly.38 Patient
information from two additional trials, MARISA and an early
trial comparing ranolazine to atenolol,30,31 was added to study
outcomes among women. Overall, data from these four trials
demonstrated that the favorable effects of ranolazine were
somewhat diminished in women, with less improvement than
men in exercise testing, but similar improvements in angina
frequency, nitroglycerin consumption, and Seattle Angina
Questionnaire angina frequency scores.39
Recently, the TERISA (Type 2 Diabetes Evaluation of
Ranolazine in Subjects With Chronic Stable Angina) trial
was completed to evaluate the performance of ranolazine in
patients with diabetes, coronary artery disease, and CSA.40
After a single-blind, 4-week placebo run-in, 949 patients
(on one or two antianginal medications) were randomized
to treatment with ranolazine ER 1,000 mg twice daily or
placebo. After 8 weeks, the average weekly number of angina
episodes (primary endpoint) was significantly reduced in the
ranolazine-treated arm compared with placebo, as was the
need for sublingual nitroglycerin. Therefore, ranolazine was
proven to retain significant benefits among diabetic patients,
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although the overall magnitude of effects was somewhat
diminished compared with previous studies.

Ranolazine in acute coronary
syndromes
The randomized, double-blind, multinational MERLIN
(Metabolic Efficiency with Ranolazine for Less Ischemia
in Non-ST-Elevation Acute Coronary Syndrome)-TIMI
(Thrombolysis In Myocardial Infarction) 36 trial was
designed to examine the safety and efficacy of ranolazine in
an acute coronary syndrome population already receiving
conventional treatment.41 In all, 6,560 patients were randomized within 48 hours of angina onset to additionally receive
ranolazine (intravenously for the first 96 hours and then
orally 1,000 mg ER twice daily), or placebo for a median of
348 days. Although no beneficial effect of ranolazine was
noted on the composite of cardiovascular death, myocardial
infarction, or recurrent ischemia (primary efficacy endpoint),
the incidence of recurrent ischemia alone was significantly
lower in the ranolazine group, as was the rate of worsening
angina requiring intensification of medical therapy.42 Mean
Seattle Angina Questionnaire scores for angina frequency
(at 4 and 12 months), quality of life, and treatment satisfaction (at 12 months) were significantly improved with ranolazine ER than with placebo.43 Similar to the overall trial
results, the risk of recurrent ischemia, worsening angina, and
intensification of antianginal therapy were all significantly
reduced in patients with prior CSA. In the subgroup of CSA
patients evaluated by exercise treadmill testing at 8 months,
the mean total exercise duration and times to onset of angina
or $1 mm ST-segment depression were significantly greater
with ranolazine ER, consistent with prior studies.
Improvements in several domains of patient-reported
angina-related health status and quality of life were seen
with ranolazine ER in these CSA patients. Of note, among
patients without CSA prior to their acute event, no such significant treatment effects were reported. Another subgroup
analysis in those who underwent percutaneous coronary
intervention within 30 days of randomization, showed a 27%
reduction in the composite primary endpoint, driven by significant reductions in recurrent ischemia and cardiovascular
death. Recurrent ischemia and recurrent ischemia requiring
repeat revascularization were also significantly reduced.
Based on these findings, RIVER-PCI (Ranolazine for
Incomplete Vessel Revascularization Post–Percutaneous
Coronary Intervention), a randomized, double-blind, Phase III,
international study of approximately 2,600 participants, is
currently ongoing to evaluate the efficacy of ranolazine in
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reducing ischemia-driven revascularization or hospitalization
in patients with CSA and incomplete revascularization after
percutaneous coronary intervention.44
As the MERLIN-TIMI 36 trial enrolled a higher risk
cohort in comparison with previous trials among stable ischemic heart disease patients, special attention was paid to the
safety of ranolazine. Overall, all-cause mortality (at 6, 12,
or 18 months) was similar in the ranolazine and placebo
groups, as was the incidence of death or any cardiovascular
hospitalization, or sudden cardiac death. The incidence of
symptomatic documented arrhythmias over the duration of
the study was also similar, although clinically significant
arrhythmias were observed less frequently during Holter
monitoring in the first 7 days with ranolazine group versus
placebo. Adverse events leading to discontinuation of medication were significantly more common in the ranolazine
group (8.1% versus 4.1% for placebo), with dizziness,
nausea, and constipation being most commonly reported.
Unfortunately, there are not much data regarding the safety
of ranolazine in special populations, especially the elderly.
In summary, no significant benefit of ranolazine compared
with placebo was seen in this trial of patients with non-STsegment elevation acute coronary syndrome with respect to
the primary efficacy endpoints, although ranolazine appeared
to be relatively safe and well tolerated.

Role of ranolazine in patients
with diastolic dysfunction
Considering its effect on the INaL, ranolazine could
potentially affect diastolic function by promoting calcium
extrusion through the sodium calcium exchanger, thus improving diastolic tension and relaxation. A study by Figueredo
et al assessed echocardiographic parameters of systolic and
diastolic function before and 2 months after initiation of
ranolazine in 22 patients with CSA. There were significant
improvements in global left ventricular function, as assessed
by myocardial performance index and diastolic function in
patients who received ranolazine.45 More recently, the RALIDHF (RAnoLazIne for the Treatment of Diastolic Heart
Failure) study was published.46 This was a small, prospective,
randomized, double-blind, placebo-controlled, proof-of-concept study of 20 patients with symptoms of congestive heart
failure, preserved left ventricular ejection fraction (.45%),
and laboratory, echocardiographic, or hemodynamic evidence of elevated filling pressures. Treatment consisted of
intravenous infusion of ranolazine for 24 hours, followed by
oral treatment for 13 days versus placebo. Left ventricular
end-diastolic pressure and pulmonary capillary wedge pres-
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sure decreased in the ranolazine group, but not in the placebo
group. After 14 days of treatment, no significant changes were
observed in echocardiographic or cardiopulmonary exercise
test parameters. Thus, this study failed to provide evidence
of any substantial expected clinical benefit from ranolazine
in this specific population.

premature ventricular complexes (PVCs) with a minimum
PVC b urden .10% on 24-hour Holter monitoring received
ranolazine which resulted in a median decrease in PVC burden of 60.2% (P=0.06).58 These findings are supportive of
further studies specifically designed to address the hypothesis
that ranolazine has antiarrhythmic effects in the ventricle.

Ranolazine as an
antiarrhythmic agent

Cost-effectiveness

The fairly selective blocking effect of the late sodium current
led to the investigation of ranolazine as a novel antiarrhythmic
agent.13–47 In a secondary analysis of the MERLIN-TIMI 36
trial, ranolazine was associated with significant reductions
in supraventricular tachyarrhythmias (P,0.001) as well as
a 30% reduction in new-onset atrial fibrillation (P,0.08).48
Small studies have suggested a role for ranolazine as a
potential treatment for atrial fibrillation, facilitating electrical
cardioversion in cardioversion-resistant patients, and as a
potential “pill-in-the-pocket” approach.49–51 Additionally,
one study showed a potential synergistic effect between
ranolazine and dronedarone for suppressing arrhythmia.52
In an observational study by Miles et al, ranolazine was
found to be more effective than amiodarone in preventing
postoperative atrial fibrillation (15% versus 25%).53 Based on
these findings, there are two large randomized clinical trials,
ie, RAFFAELLO (Ranolazine in Atrial Fibrillation Following
An ELectricaL CardiOversion), currently u nderway
examining the efficacy of ranolazine in maintaining sinus
rhythm in patients with atrial fibrillation, and HARMONY
(A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients
With Paroxysmal Atrial Fibrillation).54,55
In the future, ranolazine may become an alternative option
for treatment of ventricular arrhythmias. Data from continuous electrocardiographic monitoring in the MERLIN-TIMI
36 study showed that ranolazine significantly suppressed
episodes of ventricular tachycardia of more than eight beats
(P,0.001).48 In a small size, nonrandomized study, Bunch et al
analyzed data from 12 patients with ventricular tachycardia
refractory to antiarrhythmic drugs. Ranolazine proved effective
in reducing ventricular tachycardia burden and shocks from
implantable cardioverter defibrillators.56 Of note, the mean
QRS and the QTc interval increased nonsignificantly.
In patients with LQT3 (long QT syndrome type 3),
a monogenic disorder in which the electrophysiological
phenotype is due to an increase in INaL, ranolazine has
been shown to cause a dose-dependent abbreviation of the
QTc.57 Lastly, a study of eight patients with symptomatic
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Several cost-effectiveness analyses have been performed, with
results favoring greater use of ranolazine. In one study utilizing a large US commercial insurance claims database, cost
comparisons were made between three groups of patients,
ie, those on long-acting nitrates, those on beta-blockers or
calcium channel blockers, and those on ranolazine. After the
index event (ie, change in antianginal therapy), ranolazine
users had lower revascularization rates than the other groups,
leading to significantly lower total costs of care.59
Another study examined the cost-effectiveness of adding
ranolazine to standard-of-care antianginal therapy in patients
experiencing three or more attacks per week. The incremental
cost-effectiveness ratio for one patient for the addition of
ranolazine was $32,682 per quality-adjusted life year (QALY),
which is less than the $50,000 per QALY traditionally considered to be the threshold for cost-effectiveness.60 Finally, in a
European study, the cost-utility of ranolazine versus placebo
was computed as an add-on therapy for symptomatic chronic
angina pectoris. The incremental cost-utility ratio was 8,455
Euros per QALY per patient, which is considerably less than
the conventional willingness-to-pay threshold of 15,000 Euros
per QALY.61 In summary, ranolazine therapy appears to be
cost-effective over a variety of health care systems, likely by
reducing angina-related hospitalization and revascularization,
and improving quality of life.

Conclusion
Ranolazine is a relatively new agent added to the limited
armamentarium for treatment of CSA. Its lack of significant
impact on blood pressure and heart rate make it an attractive
drug to utilize in different clinical scenarios. In recent years,
multiple, randomized, placebo-controlled clinical trials
have confirmed its benefit in patients with CSA, improving
functional capacity and decreasing anginal episodes. At this
time, there is no clear evidence in favor of using ranolazine
in the treatment of acute coronary syndromes, as shown in
MERLIN-TIMI 36. Also, there are not sufficient data to
recommend its use for patients with congestive heart failure.
On the other hand, its effect on the INaL is quite promising
for the electrophysiology community, as some evidence
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exists that ranolazine can decrease the incidence of atrial
fibrillation and ventricular tachyarrhythmias. In summary,
ranolazine appears to be a drug with an acceptable safety
profile, a clear role in the treatment of CSA, and significant
potential for use in patients with arrhythmias.
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